Literature DB >> 10984198

Community-acquired pneumonia in the elderly: a practical guide to treatment.

D Lieberman1, D Lieberman1.   

Abstract

The incidence of community-acquired pneumonia (CAP), an infectious disease, sharply increases among the elderly and the main risk factor for CAP in this age group is chronic comorbidity. The use of the term CAP in the elderly population should be reserved for pneumonia acquired outside of the nursing home setting, since nursing home-acquired pneumonia differs from CAP in terms of its aetiology and clinical manifestations. The main aetiology for CAP is Streptococcus pneumoniae, but atypical pathogens also play an important role as causative agents. The clinical presentations of CAP in the elderly can be different from those in younger patients, and therefore it is important to be aware of and familiar with these differences to avoid unnecessary delays in reaching the correct diagnosis. Imaging is essential to diagnose CAP and to assess its severity. Clinical and laboratory indices can be used to identify elderly patients with CAP who are at low risk for mortality and who can be treated as outpatients. The decision not to hospitalise elderly patients with CAP is contingent on a good clinical condition and the existence of home support systems. The aetiology of CAP cannot be determined on the basis of clinical manifestations, imaging or routine laboratory test results, and the initial antibiotic therapy for elderly patients with CAP should be empirical, based on accepted guidelines. In the light of developments in recent years, elderly patients with CAP, except those who are severely ill, can be treated empirically with once-daily antibiotic monotherapy in the initial phase, using a third-generation fluoroquinolone preparation, such as sparfloxacin, levofloxacin or moxifloxacin, or a new macrolide such as clarithromycin, azithromycin or dirithromycin. In addition to antibiotic therapy, it is critically important to identify and treat the physiological disturbances that accompany CAP as well as decompensation of chronic comorbid conditions. As soon as the patient's condition permits, oral antibiotic therapy should replace intravenous therapy and early discharge from the hospital should be considered. Since influenza and pneumococcus immunisation can reduce morbidity and mortality from CAP, it is important to implement regular immunisation programmes in the primary care setting.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10984198     DOI: 10.2165/00002512-200017020-00002

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  69 in total

Review 1.  Atypical pathogens in community-acquired pneumonia.

Authors:  D Lieberman
Journal:  Clin Chest Med       Date:  1999-09       Impact factor: 2.878

2.  Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis.

Authors:  K Omidvari; B P de Boisblanc; G Karam; S Nelson; E Haponik; W Summer
Journal:  Respir Med       Date:  1998-08       Impact factor: 3.415

3.  Relationship of smoking history and pulmonary function tests to tracheal mucous velocity in nonsmokers, young smokers, ex-smokers, and patients with chronic bronchitis.

Authors:  R M Goodman; B M Yergin; J F Landa; M H Golivanux; M A Sackner
Journal:  Am Rev Respir Dis       Date:  1978-02

4.  Causes of pneumonia presenting to a district general hospital.

Authors:  R J White; A D Blainey; K J Harrison; S K Clarke
Journal:  Thorax       Date:  1981-08       Impact factor: 9.139

5.  Sparfloxacin versus cefaclor in the treatment of patients with community-acquired pneumonia: a randomized, double-masked, comparative, multicenter study.

Authors:  G R Donowitz; M L Brandon; J P Salisbury; C P Harman; D M Tipping; A E Urick; G H Talbot
Journal:  Clin Ther       Date:  1997 Sep-Oct       Impact factor: 3.393

6.  High resolution CT findings in community-acquired pneumonia.

Authors:  N Tanaka; T Matsumoto; T Kuramitsu; H Nakaki; K Ito; H Uchisako; G Miura; N Matsunaga; K Yamakawa
Journal:  J Comput Assist Tomogr       Date:  1996 Jul-Aug       Impact factor: 1.826

7.  A hospital study of community acquired pneumonia in the elderly.

Authors:  P Venkatesan; J Gladman; J T Macfarlane; D Barer; P Berman; W Kinnear; R G Finch
Journal:  Thorax       Date:  1990-04       Impact factor: 9.139

Review 8.  Pneumonia in the elderly.

Authors:  M S Niederman; A M Fein
Journal:  Clin Geriatr Med       Date:  1986-05       Impact factor: 3.076

9.  Community-acquired pneumonia in older patients.

Authors:  J P Janssens; L Gauthey; F Herrmann; L Tkatch; J P Michel
Journal:  J Am Geriatr Soc       Date:  1996-05       Impact factor: 5.562

10.  Clarithromycin versus amoxicillin-clavulanic acid in the treatment of community-acquired pneumonia.

Authors:  D Genné; H H Siegrist; L Humair; B Janin-Jaquat; A de Torrenté
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1997-11       Impact factor: 5.103

View more
  3 in total

1.  "I really should've gone to the doctor": older adults and family caregivers describe their experiences with community-acquired pneumonia.

Authors:  Caralyn Kelly; Paul Krueger; Lynne Lohfeld; Mark Loeb; H Gayle Edward
Journal:  BMC Fam Pract       Date:  2006-05-05       Impact factor: 2.497

Review 2.  A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP).

Authors:  Anna M Ferrara
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

3.  Comparative Outcome Analysis of Penicillin-Based Versus Fluoroquinolone-Based Antibiotic Therapy for Community-Acquired Pneumonia: A Nationwide Population-Based Cohort Study.

Authors:  Chi-Chuan Wang; Chia-Hui Lin; Kuan-Yin Lin; Yu-Chung Chuang; Wang-Huei Sheng
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.